Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07346157 · ClinicalTrials.gov registry record · Phase 1
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
A Phase 1 study, sponsored by Sabine Mueller, MD, PhD.
- Not yet
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT07346157 is a Phase 1 study that has not yet begun recruiting, run by Sabine Mueller, MD, PhD. The registered enrollment target is 69 participants.
The verdict
NCT07346157, a Phase 1 study, has not yet begun recruiting, sponsored by Sabine Mueller, MD, PhD.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront therapy.
Interventions
- DRUG Bevacizumab
- DRUG Irinotecan
- DRUG Temozolomide (TMZ)
- DRUG Liothyronine (L-T3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2026-07-30 |
| Est. Completion | 2031-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07346157
The ClinicalTrials.gov registry entry for NCT07346157 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sabine Mueller, MD, PhD, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT07346157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07346157 about?
NCT07346157 is a clinical study titled "Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease". This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront therapy.
What is the current status of trial NCT07346157?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2026-07-30. Estimated completion is 2031-03-31.
What interventions are being tested in trial NCT07346157?
The interventions under investigation include: Bevacizumab (DRUG), Irinotecan (DRUG), Temozolomide (TMZ) (DRUG), Liothyronine (L-T3) (DRUG).
Who is sponsoring clinical trial NCT07346157?
This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.